Dinaciclib
Dinaciclib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target cyclin-dependent kinase 2, cyclin-dependent kinase 9, cyclin-dependent kinase 5, and cyclin-dependent kinase 1.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
18 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Multiple myeloma | D009101 | C90.0 | 3 | 1 | — | — | — | 4 | |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 1 | — | — | — | 3 |
Myeloid leukemia acute | D015470 | C92.0 | 1 | 1 | — | — | — | 2 | |
Melanoma | D008545 | 1 | 2 | — | — | — | 2 | ||
Mantle-cell lymphoma | D020522 | C83.1 | — | 1 | — | — | — | 1 | |
Non-small-cell lung carcinoma | D002289 | — | 1 | — | — | — | 1 | ||
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | — | 1 | — | — | — | 1 | |
Prolymphocytic leukemia | D015463 | 1 | 1 | — | — | — | 1 | ||
Lentigo | D007911 | L81.4 | — | 1 | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | DINACICLIB |
INN | dinaciclib |
Description | 2-[(2S)-1-[3-ethyl-7-[(1-oxido-3-pyridin-1-iumyl)methylamino]-5-pyrazolo[1,5-a]pyrimidinyl]-2-piperidinyl]ethanol is a pyrazolopyrimidine. |
Classification | Small molecule |
Drug class | cyclin dependent kinase inhibitors (formerly-cidib) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12 |
Identifiers
PDB | — |
CAS-ID | 779353-01-4 |
RxCUI | — |
ChEMBL ID | CHEMBL2103840 |
ChEBI ID | — |
PubChem CID | 46926350 |
DrugBank | DB12021 |
UNII ID | 4V8ECV0NBQ (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CDK2
CDK2
CDK9
CDK9
CDK5
CDK5
CDK1
CDK1
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,428 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
18 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more